Table 1 Demographics and clinical characteristics of the subjects
HHT (n = 36) | Controls (n = 18) | ||
|---|---|---|---|
Age (mean, SD) | 60.2 (10.4) | 59.7 (10.2) | p = 0.868 |
Sex (males, %) | 26 (72%) | 13 (72%) | p = 1 |
History of severe infection (n, %) | 18 (50%) | 0 (0%) | |
Mutation (n, %): | |||
ENG | 18 (50%) | ||
ACVRL1 | 16 (44%) | ||
SMAD4 | 0 (0%) | ||
Not identified | 2 (6%) | ||
Visible telangiectases (median, min–max) | 70 (0–242) | ||
Epistaxis frequency1 (n, %) | |||
Daily | 13 (36%) | ||
Weekly | 13 (36%) | ||
Monthly or more rarely | 10 (28%) | ||
Arteriovenous malformations (n, %2) | |||
Lung3 | 12 (34%) | ||
Digestive tract | 19 (73%) | ||
Liver | 15 (44%) | ||
Brain | 6 (25%) | ||
Treatment (n, %) | |||
IV iron or blood transfusion (at least 5) | 20 (56%) | ||
Tranexamic acid | 6 (17%) | ||
Bevacizumab | 4 (11%) | ||